Merck KGaA, Threshold win fast track for pancreatic cancer drug
May 12, 2015 at 06:27 AM EDT
FRANKFURT, May 12 (Reuters) - Germany's Merck KGaA said that experimental cancer drug evofosfamide, which it is jointly developing with Threshold Pharmaceuticals, won fast track status for the treatment of advanced pancreatic cancer from the U.S. Food and Drug Administration.
